Navigation Links
Undertreatment of common heart condition persists despite rapid adoption of novel therapies
Date:9/21/2012

A novel blood thinner recently approved by the FDA, dabigatran (Pradaxa), has been rapidly adopted into clinical practice, yet thus far has had little impact on improving treatment rates for atrial fibrillation. This is according to a new study led by researchers from the Johns Hopkins Bloomberg School of Public Health that examined national trends in oral anticoagulant use. They found that despite rapid adoption of dabigatran for the treatment of atrial fibrillation, a large proportion of patientstwo in fivedid not receive oral anticoagulant therapy. In addition, although the majority of dabigatran utilization was for its FDA-approved indication, atrial fibrillation, an increasing proportion of use was for off-label indications such as venous thromboembolism. The results are featured in the September 2012 issue of Circulation: Cardiovascular Quality and Outcomes.

"Dabigatran has been briskly adopted into clinical practice since its October 2010 Food and Drug Administration approval for the prevention of stroke among patients with non-valvular atrial fibrillation," said G. Caleb Alexander, MD, MS, lead author of the study and a research scientist in the Bloomberg School's Department of Epidemiology. "Between 2007 and 2011, use of the oral anticoagulant warfarin declined from approximately 2.1 million quarterly physician visits to approximately 1.6 million visits while since its release, dabigatran use increased from 3.1 percent to 18.9 percent of physician visits where an oral anticoagulant was used."

Using data from the IMS National Disease and Therapeutic Index, a nationally representative audit of ambulatory providers, Alexander and colleagues quantified patterns of oral anticoagulant use among subjects between 2007 and 2011. Focusing on the oral anticoagulant drugs, dabigatran and warfarin, they examined treatment patterns by patient age, provider specialty and common indications for oral anticoagulation. Pharmacy expenditures for w
'/>"/>

Contact: Natalie Wood-Wright
nwoodwri@jhsph.edu
410-614-6029
Johns Hopkins University Bloomberg School of Public Health
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Texting in College Classrooms Common, Distracting
2. Recovery from propofol anesthesia may be sped by use of common stimulant
3. Long-term neuropsychological impairment is common in acute lung injury survivors
4. Overuse Injuries Common Among Female College Athletes
5. Common Blood Pressure Drug Safe for Heart Failure: Study
6. Test links strains of common parasite to severe illness in US newborns
7. Common Plastics Chemical Might Boost Diabetes Risk
8. Off-Label Drug Use Appears Common
9. Global, common approach to pharmaceutical supply chain integrity the focus of workshop
10. Slow-growing babies more likely in normal-weight women; Less common in obese pregnancies
11. Common Blood Pressure Drugs May Not Cut Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... 2014 (HealthDay News) -- As gas prices rose in ... new study suggests. In times of gas increases, ... riders are inexperienced, the researchers explained. They examined ... has the highest number of motorcycle registrations in the ... deaths. The analysis revealed a strong association between ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... of $5.2 Million Lifted, SALT LAKE CITY, ... ), the only U.S.-based publicly traded manufacturer of,digital ... subsidiary,successfully negotiated an amendment with Commerzbank AG, a ... acquisition of the German subsidiary. The,amendment resulted in ...
... but researchers from Tel Aviv University have found good reasons ... Dr. Liran Levin, a dentist from the Department of Oral ... found that about 15 to 20 percent of teens with ... and gum disease. Resulting tooth fractures as well as periodontal ...
... of Physicians (ACP) today commended the Medicare Payment Advisory ... primary care in a well-functioning health-care delivery system in ... MedPAC in a letter to Glen D. Hackbarth, chairman ... the U.S. Congress on issues affecting the Medicare program. ...
... boys , , FRIDAY, June 20 (HealthDay News) -- Summer ... is gearing up to warn players and their fans ... Baseball, the Major League Baseball Players Association and the ... 10th annual Play Sun Smart campaign on that day, ...
... 20 A team of medical,professionals from the ... services in Germany impressive. The NRH team has ... the US Army,s Europe Regional,Medical Command (ERMC) in ... and capability of our military health care system ...
... . , Finger ring dosemeters are used at diverse ... order to check whether the effective dose limt values are ... been subjected to an annual quality control by the PTB ... in Germany have passed these controls. , In Germany, ...
Cached Medicine News:Health News:Sonic Innovations Announces Loan Amendment With German Bank 2Health News:Sonic Innovations Announces Loan Amendment With German Bank 3Health News:Warning for teens: Teeth and jewelry don't mix 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 3Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 2Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 2Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 4Health News:PTB testing method for finger ring dosemeters has proven its effectiveness 2
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... YORK, March 31, 2011 Intercept Pharmaceuticals, Inc., today ... double-blind  Phase II clinical trial of obeticholic acid (OCA) ... (PBC).  The study evaluated the effects of 10 mg ... patients with elevated alkaline phosphatase (AP).  AP is a ...
... Services Corp., a leading provider of pharmaceutical product ... of Dean Shirazi, Ph.D., to Vice President, Analytical ... 4, 2011. (Logo:   https://photos.prnewswire.com/prnh/20110330/CG74146LOGO ) ... in June 1992 as a Senior Scientist, has ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 3AAIPharma Services Announces Promotion of Dean Shirazi 2
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
S.O.C. Medium...
... rHead Radial Implant System provides todays ... to radial head replacement. Modular ... patient anatomy while minimizing ligamentous and ... designed alignment guide assists in both ...
Medicine Products: